Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering

Attovia Therapeutics (Nasdaq: ATTO) priced its upsized initial public offering at $17.00 per share, offering 17,000,000 shares of common stock.

Rhea-AI Summary

Attovia Therapeutics (Nasdaq: ATTO) priced its upsized initial public offering at $17.00 per share, offering 17,000,000 shares of common stock. Expected gross proceeds are $289.0 million before underwriting discounts, commissions and expenses, with all shares sold by Attovia.

The company granted underwriters a 30-day option to buy up to an additional 2,550,000 shares at the IPO price, less underwriting discounts and commissions. Attovia’s stock is expected to begin trading on the Nasdaq Global Market on August 5, 2026, under the symbol “ATTO”, with closing anticipated on August 6, 2026, subject to customary conditions. Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets are joint book-running managers, and LifeSci Capital is passive book-running manager.

Positive

• IPO gross proceeds expected at $289.0 million before expenses
• 17,000,000 shares sold by the company, providing primary capital
• Underwriters granted 30-day option for up to 2,550,000 additional shares
• Listing on Nasdaq Global Market under symbol ATTO on August 5, 2026

Negative

• None.

Argus Aug 5 session 16 alerts

+10949900.00% close to close 415.6x rel. volume Open Argus

Details

Market move: ATTO +10949900.00% in the Aug 5 session. upsized initial public offering

+4.1% Peak in 1 hr 31 min

On Aug 5, the first trading day after this news, ATTO closed 10949900.00% above the previous close. Argus tracked a peak move of +4.1% during that session. Our momentum scanner recorded 16 alerts for this stock that day. Relative volume reached 415.6x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 5 session.

Key Figures

Shares offered: 17,000,000 shares IPO price: $17.00 per share Gross proceeds: $289.0 million +4 more

Shares offered

17,000,000 shares

Initial public offering

IPO price

$17.00 per share

Initial public offering

Gross proceeds

$289.0 million

Before underwriting discounts, commissions and offering expenses

Underwriter option

2,550,000 shares

30-day option at the IPO price, less discounts and commissions

Expected trading date

August 5, 2026

Expected Nasdaq Global Market listing

Expected closing date

August 6, 2026

Subject to customary closing conditions

Registration effectiveness

August 4, 2026

Registration statement declared effective by the SEC

Key Terms

initial public offering, underwriting discounts and commissions, joint book-running managers, registration statement

4 terms

initial public offering financial

"pricing of its upsized initial public offering of 17,000,000 shares"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

underwriting discounts and commissions financial

"before deducting underwriting discounts and commissions and other offering expenses"

Underwriting discounts and commissions are fees paid to financial institutions that help sell new securities to investors. They act like a commission for their role in connecting companies with buyers, often reducing the amount of money the issuing company raises. For investors, understanding these costs helps gauge how much of their investment is going toward the actual securities versus fees paid to middlemen.

joint book-running managers financial

"are acting as joint book-running managers for the offering"

Joint book-running managers are the lead banks or financial firms responsible for organizing and overseeing the sale of a large financial offering, such as a company’s stock or bonds. They coordinate efforts to set the price, attract investors, and ensure the offering is successful. Their role is important to investors because they help ensure the offering is well-managed, properly priced, and accessible to a wide range of buyers.

registration statement regulatory

"A registration statement relating to these securities has been filed"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN CARLOS, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the pricing of its upsized initial public offering of 17,000,000 shares of its common stock at an initial public offering price of $17.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $289.0 million. All shares of common stock to be sold in the offering will be sold by Attovia. In addition, Attovia has granted the underwriters a 30-day option to purchase up to an additional 2,550,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Attovia’s common stock is expected to begin trading on the Nasdaq Global Market on August 5, 2026, under the symbol “ATTO.” The offering is expected to close on August 6, 2026, subject to the satisfaction of customary closing conditions.

Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets are acting as joint book-running managers for the offering. LifeSci Capital is acting as a passive book-running manager for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on August 4, 2026. The offering is being made only by means of a prospectus. A copy of the final prospectus may be obtained, when available, from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, Second Floor, New York, NY 10014 or by email at prospectus@morganstanley.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ext. 6105 or by email at syndicate@leerink.com; Citigroup Global Markets, Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 1-800-831-9146; and RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, by telephone at 1-877-822-4089 or by email at equityprospectus@rbccm.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Attovia, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

About Attovia Therapeutics, Inc.

Attovia is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using our ATTOBODY biparatopic biologics platform. Attovia’s ATTOBODY platform uses an evolution-driven, high-throughput process which allows for rapid discovery and creation of a high diversity of potential product candidates.

Attovia’s lead programs include ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases, ATTO-2306, a bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases, and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7 in IND-enabling studies for inflammatory bowel disease. Attovia’s other programs include highly innovative conditional ‘AND’ gated bispecific immune cell survival blockers and multispecifics.

Investor and Media Contact
PJ Kelleher
LifeSci Advisors
617-430-7579
pkelleher@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the key terms of Attovia Therapeutics (ATTO) IPO priced on August 4, 2026?

Attovia Therapeutics priced its upsized IPO at $17.00 per share for 17,000,000 shares. According to Attovia, expected gross proceeds are $289.0 million before underwriting discounts, commissions and other offering expenses, with all shares sold by the company.

How much money will Attovia Therapeutics (NASDAQ: ATTO) raise from its IPO?

Attovia Therapeutics expects to raise $289.0 million in gross proceeds from its IPO. According to Attovia, this figure is before deducting underwriting discounts, commissions and other offering expenses, and excludes any additional proceeds from the underwriters’ option.

When will Attovia Therapeutics (ATTO) start trading on the Nasdaq after its IPO?

Attovia Therapeutics common stock is expected to begin trading on the Nasdaq Global Market on August 5, 2026 under the symbol ATTO. According to Attovia, the offering is expected to close on August 6, 2026, subject to customary closing conditions.

What is the underwriters’ option in the Attovia Therapeutics (ATTO) IPO?

Underwriters have a 30-day option to purchase up to 2,550,000 additional Attovia shares at the IPO price. According to Attovia, this option is exercisable at $17.00 per share, less underwriting discounts and commissions, potentially increasing total shares sold.

Who are the underwriters for the Attovia Therapeutics (NASDAQ: ATTO) initial public offering?

Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets are joint book-running managers for the Attovia IPO. According to Attovia, LifeSci Capital acts as a passive book-running manager, supporting the offering’s distribution and execution in the capital markets.

Is the Attovia Therapeutics (ATTO) IPO registered with the SEC?

Yes, the Attovia Therapeutics IPO is registered with the U.S. SEC. According to Attovia, a registration statement for these securities was filed and declared effective on August 4, 2026, and the offering is made only by means of a prospectus.

Are all shares in the Attovia Therapeutics IPO primary shares issued by the company?

All IPO shares are being sold by Attovia as primary shares issued by the company. According to Attovia, no existing stockholders are selling shares in this offering, meaning proceeds before expenses will go directly to the company.